The rise of cognitive therapy rankles psychotherapists and psychiatrists who ply the retrospective analysis and soulful conversation, whose origins date back to Sigmund Freud and the 1890s.

FORBES: Patient Fix Thyself

Lilly, however, noted that a pre-specified secondary analysis of pooled data showed statistically significant slowing of cognitive decline in patients with mild-to-moderate disease who were treated with its solanezumab compound.

FORBES: Lilly's Big Alzheimer's Bet: Will It Pay Off?

While the primary endpoints of the two pivotal studies conducted were not met, a secondary analysis of the data demonstrated that a molecule acting specifically on amyloid-beta can slow cognitive decline in patients with mild AD.

FORBES: Solving The Fatal Puzzle Of Alzheimer's Disease